A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?

A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?

Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.

Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products.